1. Home
  2. CTW vs VRXA Comparison

CTW vs VRXA Comparison

Compare CTW & VRXA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CTW Cayman Class A Ordinary Shares

CTW

CTW Cayman Class A Ordinary Shares

SELL

Current Price

$1.51

Market Cap

171.0M

Sector

Technology

ML Signal

SELL

Logo Veraxa Biotech AG Ordinary Shares

VRXA

Veraxa Biotech AG Ordinary Shares

HOLD

Current Price

$1.10

Market Cap

161.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTW
VRXA
Founded
2013
2021
Country
Japan
Germany
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
171.0M
161.2M
IPO Year
2025
2025

Fundamental Metrics

Financial Performance
Metric
CTW
VRXA
Price
$1.51
$1.10
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
12.9K
★ 152.5K
Earning Date
10-15-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$22.41
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.10
$0.90
52 Week High
$3.10
$4.50

Technical Indicators

Market Signals
Indicator
CTW
VRXA
Relative Strength Index (RSI) 34.64 47.20
Support Level $1.50 $0.96
Resistance Level $1.99 $1.25
Average True Range (ATR) 0.21 0.12
MACD -0.01 0.03
Stochastic Oscillator 1.02 38.39

Price Performance

Historical Comparison
CTW
VRXA

About CTW CTW Cayman Class A Ordinary Shares

CTW operates as a gaming platform company providing instant access to free-to-play, browser-based games inspired by popular Japanese animation, including "So I'm a Spider, So What? Ruler of the Labyrinth, Arifureta: From Commonplace to World's Strongest - Rebellion Soul", and "Queen's Blade Limit Break". CTW delivers these games through its flagship HTML5 platform, G123.jp.

About VRXA Veraxa Biotech AG Ordinary Shares

Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.

Share on Social Networks: